Dr. Reckamp Describes the Use of Heat Shock Proteins

Partner | Cancer Centers | <b>City of Hope</b>

Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes early studies in lung cancer that examine heat shock proteins as single agents, specifically in ALK translocated patients and some EGFR wild type adenocarcinoma patients, which are less well defined. The proteins have shown success when used as a single agent when there is a resistance to crizotinib. Studies are currently underway that are investigating heat shock proteins in chemotherapy combination therapies.